A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atumelnant (Primary)
Indications Cushing syndrome; Ectopic ACTH syndrome; Pituitary ACTH hypersecretion
Focus Adverse reactions; Pharmacokinetics
Sponsors Crinetics Pharmaceuticals

03 Jun 2024 According to a Crinetics Pharmaceuticals media release, Initial data from five ACTH-dependent Cushing's syndrome trial participants, presented at the Endocrine Society's annual meeting (ENDO2024).
08 May 2024 According to a Crinetics Pharmaceuticals media release, data from the study will be presented at the Endocrine Societys annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston, Massachusetts.
07 Nov 2023 According to Crinetics Pharmaceuticals media release, Data from the study are expected in the second half of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com